Biocracked
**Approach: Conceptual metaphor. Palette: D, bold color field.**

A single clear glass of water sits on a saturated mustard-yellow backdrop, shot at a slight low three-quarter angle. A hand-held pen injector rests beside it, its body a matte white with a small electric green dial ring as the only green accent. Hard but clean studio light from the upper left throws a crisp, defined shadow across the yellow surface. Through the glass, the injector is refracted into two slightly offset images, suggesting a signal that is split and hard to read. The mood is calm, questioning and balanced, with no drama. The background is fully warm and bright, with no blue cast. The surface has a subtle paper-like texture. There is no text, no label and no face.
Metabolism

Shin Ozempic da Mounjaro Suna Haifar da Tunani na Kashe Kai? Abin da Bincike 20 Ya Gano

Dr. Synapse · · 4 min read

Taken Mai Ban Tsoro vs. Bayanai

Shekaru kaɗan da suka gabata, an fara yada rahotanni na canjin yanayi da tunani na kashe kai a cikin mutanen da ke shan magungunan GLP‑1. Hukumomin kula da lafiya sun lura da wannan al'amari. Hukumar Turai ta Kula da Magunguna (EMA) da Hukumar Kula da Abinci da Magunguna ta Amurka (FDA) duk sun sake duba batun. Sabon bincike mai tsari da aka wallafa a Rambam Maimonides Medical Journal ya tattara hujjojin, kuma sakamakon da ya fito ya ba da kwanciyar hankali: gwaje‑gwajen bazuwar ba su nuna ƙaruwa a haɗarin tunani na kashe kai, damuwa ko fargaba daga masu haifar da GLP‑1 (kamar semaglutide) ko tirzepatide.

Bayani na Tsari

Abin da Masana suka Yi

Masu binciken sun duba PubMed/MEDLINE, Embase, Web of Science, da Scopus har zuwa 15 ga Maris 2026, inda suka takaita bincike zuwa waɗanda aka wallafa da Turanci, kuma suka mayar da hankali kan manya (≥18 shekara) da ke da ciwon sukari nau’in 2 ko kiba. Sun bi ka’idojin PRISMA 2020, tare da ƙarin PRISMA‑S da PRISMA‑Harms. Jimillar bincike 20 da bita biyu na hukuma suka cika ka’idojin shigarwa.

An rarraba hujjojin zuwa ƙungiyoyi biyar:

  1. Gwaje‑gwajen bazuwar (RCTs)
  2. Binciken kwatankwacin (target‑trial emulations)
  3. Binciken da ba su da kwatankwacin (observational studies)
  4. Nazarin rahoton abubuwan da suka faru marasa kyau (adverse‑event reporting)
  5. Binciken hukuma

Masu binciken sun kimanta ƙimar ƙuri’a da kayan aikin Cochrane RoB 2 da ROBINS‑I, sannan suka taƙaita sahihancin sakamako da GRADE. Sun jaddada bambanci tsakanin ganowa alama (signalling) da ƙirga dalili (causation).

Muhimman Sakamako, a Sauƙaƙe

1. Gwaje‑gwajen bazuwar: babu ƙaruwa a haɗari

Binciken meta‑analysis biyu na 2025 da kuma nazarin haɗin bayanai na semaglutide da tirzepatide sun nuna babu ɗaya daga cikin su da ya ƙara haɗarin tunani na kashe kai, damuwa ko fargaba.

2. Binciken kwatankwacin: ba a ga bambanci ba

Binciken da aka yi a Amurka, Skandinaviya, da Birtaniya sun kuma nuna babu ƙaruwa a fili bayan an daidaita abubuwan da ke rikitarwa. Tsarin kwatankwacin da ke amfani da magungunan GLP‑1 da waɗanda ke amfani da magungunan sukari ko rage kiba na daban ya ba da sakamako mai inganci.

3. Alamu masu firgita: dalilan rikice‑rikice

Wasu ƙirar bincike da suka yi ƙoƙarin ware tasirin magani daga wasu abubuwa uku ba su da ƙarfi:

  • Hatsarin kwakwalwa na asali
  • Damuwa da ke tattare da kiba
  • Kuskurar rahoto Saboda haka, waɗannan alamu ba su nuna alaƙa kai tsaye ba, sai dai suna nuna buƙatar ƙarin bincike.

4. Hukuma: ba a samu alaƙa ta ainihi ba

Kammalawar EMA da FDA, kamar yadda masu binciken suka taƙaita, ba su goyi bayan alaƙa ta ainihi tsakanin GLP‑1 RAs da tunani na kashe kai ko halayen kashe kai.

Ƙuntatawa da Abubuwan Da Za a Kula Da Su

  • Ƙuntatawar samfur: Gwaje‑gwajen sun ware mutanen da ke da cutar kwakwalwa, don haka ba su wakilci dukan al’umma ba. Mutanen da ke da damuwa ko fargaba mai tsanani suna iya kasancewa a ƙasa da wakilci a bayanan.
  • Lokaci mai tsawo: Sakamakon dogon lokaci har yanzu ba a tabbatar da su ba; akwai buƙatar sa ido na ci gaba.
  • Kiba kawai: Binciken ya fi mai da hankali kan masu kiba; sauran ƙungiyoyi kamar masu daɗaɗɗen nauyi ko yara ba a haɗa su ba.
  • Yare: An takaita binciken ga ƙwararrun Turanci, don haka wasu nazari daga ƙasashe masu amfani da harsuna daban ba su shiga ba.

Abubuwan Da Za a Iya Aiwatar Da Su A Aiki

Wannan bita ta tsaro ne ga magungunan GLP‑1 da tirzepatide, ba bincike na ƙara gina jiki ba. Ba ta ba da shawarwarin ƙuduri ko lokacin amfani ba; umarnin likita da lakabin samfurin su ne mafi sahihi.

Abin da hujjojin ke tallafawa:

  • Idan kai babba ne da ke da ciwon sukari nau’in 2 ko kiba, yanzu hujjojin ba su nuna cewa semaglutide ko tirzepatide (sinadaran da ke cikin Ozempic/Wegovy da Mounjaro/Zepbound) suna ƙara haɗarin damuwa, fargaba ko tunani na kashe kai.
  • Canjin yanayi yayin saurin rage kiba na iya faruwa saboda dalilai da dama; ka rika ba da rahoto maimakon ka ɗauka cewa ba su da haɗari ko kuma magani ne ya haifar da su.

Waɗanda ya kamata su kula da ƙari:

  • Mutanen da ke da tarihin cutar kwakwalwa mai tsanani, domin ba su wakilci sosai a gwaje‑gwajen. Ana ba da shawarar ci gaba da sa ido a wannan ƙungiya, ba tare da hana su amfani da magani ba.
  • Mutanen da ke amfani da waɗannan magungunan domin rage kiba kawai, ƙungiyar bincike na ba da shawarar a ci gaba da lura da yanayin tunani.

Waɗanda ba su da buƙatar guje wa maganin: Bita ba ta nuna kowanne rukuni da ya kamata ya guje wa Ozempic ko Mounjaro bisa ga hujjojin neuropsychiatric ba. Zaɓin magani ya dogara ne da cikakken tarihin lafiyar ku kuma yana buƙatar shawarar likita.

Idan ka lura da sabbin alamun rashin jin daɗi, damuwa ko tunani na kashe kai, tuntuɓi ƙwararren lafiya da wuri‑wuri. A Amurka, za ka iya kira ko aika saƙon rubutu zuwa 988 don layin tallafi na kashe kai da rikice‑rikice. Kada ka daina ko canza magani da kanka ba tare da shawarar likita ba.

Gabaɗayan Bayani

Mafi yawan hujjojin da aka sarrafa da kyau suna nuna abu ɗaya: babu ƙaruwa a tunani na kashe kai, damuwa ko fargaba, kuma ba a sami alaƙa da hukumomi suka tabbatar da ita ba. Alamu masu firgita sun taso ne daga ƙirar bincike da ba za su iya raba tasirin magani daga haɗarin da ke akwai da kuskuren rahoto ba. Tambayoyin da suka rage suna shafar marasa lafiya da ke da tarihin cutar kwakwalwa mai tsanani da kuma sakamakon dogon lokaci da ba su da yawa. Don waɗannan, amsar gaskiya ita ce a ci gaba da sa ido.

Wannan labarin yana taƙaita bita da aka wallafa kuma ba shawarwarin likita ba ne.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 3, the human outcome, in palette B, warm.

Low three-quarter rear angle, shot with a 50mm lens at shallow depth of field. A middle-aged person's forearm and hand grip a loaded barbell mid-deadlift, the tendons and the muscle of the forearm clearly defined, with chalk dust hanging in the air. Their face is out of frame. The setting is a plain home garage gym with a rubber floor and a rack softly blurred in the background. Low golden-hour sunlight comes through an open roll-up door and rakes across the skin and the knurled steel, casting long warm shadows. Amber, copper and honey tones dominate, with matte black plates for contrast. A tiny electric green silicone wristband or a small green pen injector resting on a nearby shelf adds a subtle accent. The mood is determined, quiet and hopeful.
metabolism

Game da Tirzepatide? Ɗaga Nauyi Ya Ceton 1.1 kg na Tsokoki

BY REX MERIDIAN ·

Tirzepatide na iya rage fiye da 22 kg a cikin makonni 40, amma yana sa a rasa ƙwayar jiki da ƙarfi. Gwajin bazuwar da ya kunshi mutane 120 ya nuna cewa, idan aka yi horon ƙarfi sau uku a mako, asarar kitse ta kasance iri ɗaya, amma an ceton kusan 1.1 kg na ƙwayar jiki mara mai kuma ƙarfi ya ƙaru.

Approach: 3, the human outcome, here as an animal-science moment. Palette: C, natural.

An old female lab mouse with slightly greying, ruffled fur sits upright on a researcher's open gloved palm, photographed at eye level in a close side-on view with a shallow depth of field. Behind it, a softly blurred animal facility window pours in real morning daylight, giving the scene a pale green-grey and warm-wood setting. The nitrile glove is a vivid electric green (#00e676), the single saturated accent. The mouse's whiskers and pink ears catch the light, and the researcher's white coat sleeve is just visible. Tones are natural: skin, soft cream bedding, sage walls. The mood is calm, careful and quietly hopeful, and it conveys age and care rather than drama. The image has no text, no labels and no readable writing.
longevity

Abin da ke cikin Ozempic ya tsawaita rayuwar berayen da suka tsufa – Ga dalilin

BY DR. SYNAPSE ·

Semaglutide, sinadarin da ke cikin Ozempic da Wegovy, ya tsawaita rayuwar berayen mata tsofaffi a wani sabon bincike da aka wallafa a *Nature* daga UC Berkeley. An ba su maganin ne a lokacin da suke da watanni 20, inda aka ga alamun rage tsufa da inganta aikin jiki. A gwajin beraye, semaglutide ya ba da sakamako mafi kyau fiye da rage kalori (CR) a kan sha’awar abinci, ƙwaƙwalwa da sarrafa sukari. Amma wannan bincike ya ƙunshi berayen mata ne kawai, ba ya nufin amfani ga mutane. Ga abin da sakamakon ke nuni da shi da abin da ba ya nuni ba.

Approach: Macro science, the human outcome angle through tissue. Palette: D, bold color field.

Extreme close-up of a cross-section of raw beef thigh muscle, used as a stand-in for human thigh tissue. It is shot straight on and slightly from above, on a saturated tomato-red seamless backdrop. Fine white fat marbling threads run through the dark red muscle fibers. On one half the marbling is dense and lacy, and on the other it is sparse and clean, so the contrast reads as a before and after. A thin, translucent calipers-style steel ruler lies along the edge, with no markings readable. Lighting is soft, directional studio light from the upper left, with crisp highlights on the glistening fibers and gentle warm shadows. A single small electric green surgical marker dot sits on the tissue. The mood is analytical, tense and uncertain, with shallow depth of field and sharp detail on the fat texture.
longevity

Semaglutide Mai Girma da Tsokar Cinyoyi: Abinda MRI Ya Nuna

BY HELIX WARD ·

Binciken MRI da aka yi a cikin gwajin STEP UP ya duba abin da ke faruwa bayan makonni 72 na amfani da semaglutide mai ƙarfi (7.2 mg) akan tsarin jiki, ciki har da tsokar cinyoyi. An sami raguwar kitse sosai, kusan lita 11 idan aka kwatanta da placebo, kuma kitse a cikin tsokar cinyoyi ya ragu sosai. Girman tsokar cinyoyi ya ragu da kusan lita 1.1, canjin da bai kai matsayin ƙididdiga ba (p = 0.07) amma tazara na dogara tana nuni da asara. Tunda an duba mutum 55 kawai, tare da placebo guda shida, kuma kamfanin Novo Nordisk ya shiga cikin binciken, sakamakon na nuni ne kawai ba tabbatacce ba.

**Approach:** Lab in action. **Palette:** Bold color field, mustard yellow.

A close, slightly high three-quarter view of a hand in a magenta-purple nitrile glove holding a clear 12-well cell culture plate. Each well is filled with salmon-pink culture medium. A multichannel pipette hovers over one well, with a single droplet caught just before it falls. The background is a seamless, saturated mustard-yellow surface and wall, with a soft shadow under the plate. Bright, even studio light comes from the upper left, giving crisp highlights on the plastic rims and a soft glow through the liquid. The depth of field is shallow, so the far wells blur gently. A tiny electric-green cap on a tube sits in the corner of the frame. The mood is calm, precise and curious, with a clean, graphic, editorial feel. No text or labels.
peptides

Semaglutide Ba Ya Rage Kwayoyin Tsoka na Dan Adam. To Me Ya Sa Akwai Rashin Tsoka?

BY DR. SYNAPSE ·

Shin semaglutide yana lalata tsokar ka? Sabon binciken *GeroScience* ya gwada maganin kai tsaye a kan ƙwayoyin tsoka na manya masu kiba, inda ba a ga wata alamar lalacewa ba. Babu alamar atrophy, babu canjin secretome, har ma GIP ya ƙara kauri ga myotubes bayan kwanaki takwas. Semaglutide ya rage ɗan ƙanƙanta samar da ATP ta glycolysis, amma GLP‑1 receptors ba su yawaita ba a ƙwayoyin. Sakamakon na nuni da cewa asarar tsoka da ake gani a asibiti na da alaƙa da ƙarancin kalori da rage ɗagawa, ba da kai tsaye ga maganin ba.

This page is available in